Valsartan
- Generic Name
- Valsartan
- Brand Names
- Dafiro, Diovan, Diovan Hct, Entresto, Exforge, Exforge Hct
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29N5O3
- CAS Number
- 137862-53-4
- Unique Ingredient Identifier
- 80M03YXJ7I
- Background
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes telmisartan, candesartan, losartan, olmesartan, and irbesartan. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and syn...
- Indication
Valsartan is indicated for the treatment of hypertension to reduce the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It is also indicated for the treatment of heart failure (NYHA class II-IV) and for left ventricular dysfunction or failure after myocardial infarction when the use of an angiotensin-converting ...
- Associated Conditions
- Cardiovascular Mortality, Diabetic Nephropathy, Heart Failure, Hypertension, Moderate Essential Hypertension, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Hospitalization due to cardiac failure
- Associated Therapies
- -
Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 12
- Registration Number
- NCT03893526
- Locations
- 🇩🇰
Hvidovre Hospital, Hvidovre, RegionH, Denmark
Effect of ARNI in Patients With Persistent AF and Enlarged Left Atrium After Catheter Ablation
- Conditions
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2019-03-19
- Target Recruit Count
- 90
- Registration Number
- NCT03791723
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
- Conditions
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT03738878
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Nighttime Valsartan in Hemodialysis Hypertension
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2018-07-20
- Target Recruit Count
- 68
- Registration Number
- NCT03594825
Role of ARNi in Ventricular Remodeling in Hypertensive LVH
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- National Heart Centre Singapore
- Target Recruit Count
- 80
- Registration Number
- NCT03553810
- Locations
- 🇸🇬
National Heart Centre Singapore, Singapore, Singapore
The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 93
- Registration Number
- NCT03552575
- Locations
- 🇬🇧
Glasgow Cardiovascular Research Centre, Glasgow, Scotland, United Kingdom
🇬🇧Glasgow Clinical Research Facility, Glasgow, Scotland, United Kingdom
Bariatric Surgery and Pharmacokinetics of Valsartan
- Conditions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03535376
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802
- Conditions
- Interventions
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- LG Chem
- Target Recruit Count
- 42
- Registration Number
- NCT03532854
- Locations
- 🇰🇷
LG chem, Seoul, Gangseo-Gu, Korea, Republic of
Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Hannover Medical School
- Registration Number
- NCT03415906
- Locations
- 🇩🇪
Clinical Research Center Hannover, Hannover Medical School, Hannover, Germany
Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- University Hospital, Limoges
- Registration Number
- NCT03315832
- Locations
- 🇫🇷
Limoges university hospital, Limoges, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.